• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Oncology
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
    • Cell & Gene Therapy
    • Drug Development
    • Small Molecule Research & Development
    • Oncology
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • Outsourcing Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
Home
Subscribe
Hamburger Menu Hamburger Menu
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Oncology
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
    • Cell & Gene Therapy
    • Drug Development
    • Small Molecule Research & Development
    • Oncology
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • Outsourcing Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Brought to you by:
sino biological

Cell & Gene Therapy

Exploring the latest news and insight around cell and gene therapy, including new technology and information on treatments. See how pharma is leveraging gene therapy and cell therapy to prevent and treat disease.

Businesspeople walking towards a bright light at the end of a white corridor
Biotech

Artiva lays off staff after deaths, durability sink cell therapy

Artiva halted development of an autoimmune disease cell therapy and laid off 94% of its staff after two patients died.
Nick Paul Taylor Oct 27, 2026 8:40am
Bristol Myers Squibb booth at AACR 2026

BMS sheds light on patient death in CAR-T trial

Oct 26, 2026 7:00am
Schinecker

Roche CEO has ‘absolutely not’ changed view on Poseida buyout

Oct 22, 2026 4:16am
China flag against blue sky

China looks to ban foreign acquisitions of key biotech platforms

Oct 16, 2026 10:38am
Estuary river tributary

Estuary emerges with $103M for kidney disease gene therapies

Oct 16, 2026 6:30am
A ballpoint pen rests on top of a stack of documents ready for signing

Rebranded Galapagos finally finds buyer for cell therapies

Oct 15, 2026 4:09am

Home
  • Connect
    • The Team
    • Advertise
    • Marketing Kit
    • Let's Talk
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Pharma
    • Fierce Biotech
    • Fierce Healthcare
  • Our Events
    • Life Sciences Events
©2026 Questex LLC All rights reserved.
Terms of use
Privacy Policy
Privacy Settings